Figure 5
- ID
- ZDB-FIG-221214-132
- Publication
- Poudel et al., 2022 - Resveratrol-Mediated Reversal of Doxorubicin-Induced Osteoclast Differentiation
- Other Figures
- (all 10)
- All Figure Page
- Back to All Figure Page
Effect of MitoTEMPO on doxorubicin-induced osteoclast differentiation. RAW 264.7 cells were cultured for 4 days with M-CSF (30 ng/mL) and RANKL (50 ng/mL) and treated with MitoTEMPO (MT) and Doxorubicin (DOX) alone or together. The cells were stained for TRAP (A). The number of TRAP-positive cells (B). Cells were grouped according to number of nuclei: 1, 2, 3 or more than 4 (≥4) (C). One-way ANOVA, Tukey’s multiple comparisons test, *—p ≤ 0.05, **—p ≤ 0.01, ***—p ≤ 0.001, ****—p ≤ 0.0001. |